



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
		Application Number	10/825,757		
		Filing Date	April 16, 2004		
		First Named Inventor	LINNEN <i>et al.</i>		
		Art Unit	1645 1634		
(Use as many sheets as necessary)		Examiner Name	To Be Assigned SALMON		
Sheet	1	of	3	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KS		Holmes, "SARS coronavirus: a new challenge for prevention and therapy," J. Clin. Invest., June 2003, 111(11):1605-1609, American Society for Clinical Investigation, USA.	
		Rota <i>et al.</i> , "Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," Science, May 30, 2003, 300:1394-1399, American Association for the Advancement of Science, USA.	
		Thiel <i>et al.</i> , "Mechanisms and enzymes involved in SARS coronavirus genome expression," J. Gen. Virol., 2003, 84:2305-2315, London Society for General Microbiology, Great Britain.	
		DATABASE GENBANK, Accession No. AF304460, Version No. AF304460.1, "Human coronavirus 229E, complete genome," July 11, 2001.	
		DATABASE GENBANK, Accession No. X69721, Version No. X69721.1, "Human coronavirus 229E mRNA for RNA polymerase and proteases," July 13, 2001.	
		DATABASE GENBANK, Accession No. NC_002645, Version No. NC_002645.1, "Human coronavirus 229E, complete genome," Jan. 12, 2004.	
		DATABASE GENBANK, Accession No. AF124989, Version No. AF124989.1, "Human coronavirus (strain OC43) RNA-directed RNA polymerase (pol) gene, partial cds.," July 13, 1999.	
		DATABASE GENBANK, Accession No. NC_004718, Version No. NC_004718.1, "SARS coronavirus, complete genome," April 25, 2003.	
		DATABASE GENBANK, Accession No. NC_004718, Version No. NC_004718.2, "SARS coronavirus, complete genome," April 25, 2003.	
		DATABASE GENBANK, Accession No. AY269391, Version No. AY269391.1, "SARS coronavirus Vietnam strain, 200300592 polymerase gene, partial cds.," April 16, 2003.	
		DATABASE GENBANK, Accession No. AY268049, Version No. AY268049.1, "SARS coronavirus Taiwan RNA-directed RNA polymerase (pol) gene, partial cds.," April 20, 2003.	
↓		DATABASE GENBANK, Accession No. AY274119, Version No. AY274119.1, "SARS coronavirus TOR2, complete genome," April 14, 2003.	

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/825,757
		Filing Date	April 16, 2004
		First Named Inventor	LINNEN <i>et al.</i>
		Art Unit	1045 1634
(Use as many sheets as necessary)		Examiner Name	To Be Assigned SALMON
Sheet	2	of	3
		Attorney Docket Number	GP146-04.UT
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KS		DATABASE GENBANK, Accession No. AY274119, Version No. AY274119.2, "SARS coronavirus TOR2, complete genome," April 23, 2003.	
		DATABASE GENBANK, Accession No. AY274119, Version No. AY274119.3, "SARS coronavirus TOR2, complete genome," March 24, 2004.	
		DATABASE GENBANK, Accession No. AY278487, Version No. AY278487.1, "SARS coronavirus BJ02, partial genome," April 21, 2003.	
		DATABASE GENBANK, Accession No. AY278487, Version No. AY278487.2, "SARS coronavirus BJ02, partial genome," June 5, 2003.	
		DATABASE GENBANK, Accession No. AY278487, Version No. AY278487.3, "SARS coronavirus BJ02, partial genome," June 5, 2003.	
		DATABASE GENBANK, Accession No. AY278488, Version No. AY278488.1, "SARS coronavirus BJ01, partial genome," April 21, 2003.	
		DATABASE GENBANK, Accession No. AY278488, Version No. AY278488.2, "SARS coronavirus BJ01, complete genome," May 1, 2003.	
		DATABASE GENBANK, Accession No. AY278489, Version No. AY278489.1, "SARS coronavirus GZ01, partial genome," April 21, 2003.	
		DATABASE GENBANK, Accession No. AY278489, Version No. AY278489.2, "SARS coronavirus GD01, complete genome," August 18, 2003.	
		DATABASE GENBANK, Accession No. AY278490, Version No. AY278490.1, "SARS coronavirus BJ03, partial genome," April 21, 2003.	
V		DATABASE GENBANK, Accession No. AY278490, Version No. AY278490.2, "SARS coronavirus BJ03, partial genome," June 5, 2003.	
		DATABASE GENBANK, Accession No. AY278490, Version No. AY278490.3, "SARS coronavirus BJ03, complete genome," June 5, 2003.	

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/825,757	
			Filing Date	April 16, 2004	
			First Named Inventor	LINNEN <i>et al.</i>	
			Art Unit	1046 1634	
(Use as many sheets as necessary)			Examiner Name	To Be Assigned SALMON	
Sheet	3	of	3	Attorney Docket Number	GP146-04.UT
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
KS		DATABASE GENBANK, Accession No. AY278491, Version No. AY278491.1, "SARS coronavirus HKU-39849, complete genome," April 18, 2003.			
		DATABASE GENBANK, Accession No. AY278491, Version No. AY278491.2, "SARS coronavirus HKU-39849, complete genome," August 29, 2003.			
		DATABASE GENBANK, Accession No. AY278554, Version No. AY278554.1, "SARS coronavirus CUHK-W1, complete genome," April 18, 2003.			
		DATABASE GENBANK, Accession No. AY278554, Version No. AY278554.2 "SARS coronavirus CUHK-W1, complete genome," July 13, 2003.			
		DATABASE GENBANK, Accession No. AY278741, Version No. AY278741.1, "SARS coronavirus Urbani, complete genome," August 12, 2003.			
		DATABASE GENBANK, Accession No. AY279354, Version No. AY279354.1, "SARS coronavirus BJ04, partial genome," April 23, 2003.			
		DATABASE GENBANK, Accession No. AY279354, Version No. AY279354.2, "SARS coronavirus BJ04, complete genome," June 5, 2003.			

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/825,757
Filing Date	April 16, 2004
First Named Inventor	LINNEN <i>et al.</i>
Art Unit	1645 1634
Examiner Name	To Be Assigned SALMON
Attorney Docket Number	GP146-04.UT

(Use as many sheets as necessary)

Sheet 1 of 9

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	6 T
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KS		CN 1450172 A	10-22-2003	Hangzhou Huada Jene Res Ct		
↓		DE 20315159 U1	01-22-2004	Artus Ges Fuer Molekularbiolog		X
↓		WO04/057021 A2	07-08-2004	Université Laval		

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1045 1634
(Use as many sheets as necessary)				Examiner Name	To Be Assigned SALMON
Sheet	2	of	9	Attorney Docket Number	GP146-04.UT
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
KS		"Artus SARS Test", ABBOTT LABORATORIES, undated, 7 pgs., USA			
		"Meeting to Discuss Development of Diagnostic Test for SARS", Seminar Held in May 29, 2003, 3 pgs., USA			
		"RAT CORONAVIRUSES, Sialodacryoadenitis Virus and Rat Coronavirus: History, Virus Classification, Clinical Disease, Pathology, Diagnosis, Control, Interference with Research and Virus Status of Experimental Rats", CRL Technical Bulletin, Oct. 1983, 2(2):1-13, USA			
		"CORONAVIRUSES, Severe Acute Respiratory Syndrome (SARS): Read the Facts", Microbiol. & Immuno., BS3035, April 2003, pgs. 1-8, USA			
		"PCR primers for SARS developed by WHO Network Laboratories", World Health Organization, 2003			
		"Cluster of Severe Acute Respiratory Syndrome Cases Among Protected Health-Care Workers--- Toronto, Canada, April 2003", CDC, May 16, 2003, MMWR 52(19):433-436, USA			
		"Guidelines for Collection of Specimens from Potential Cases of SARS", CDC, Apr. 23, 2003, pgs. 1-4, USA			
		"SARS Diagnostics: Scientific and Regulatory Challenges", PowerPoint Presentation, U.S. Department of Health and Human Services Food and Drug Administration, Jul. 14, 2003, 10 pgs., USA			
		ALEJSKA <i>et al.</i> , "How RNA viruses exchange their genetic material", Acta Biochim. Pol., 2001, 48(2):391-407, Poland			
		ALMAZAN <i>et al.</i> , "Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome", Proc. Natl. Acad. Sci., May 9, 2000, 97(10):5516-5521, USA			
		ALONSO <i>et al.</i> , "In vitro and in vivo expression of foreign genes by transmissible gastroenteritis coronavirus-derived minigenomes", J. Gen. Virol., 2002, 83:567-579, Great Britain			
		ANAND <i>et al.</i> , "Coronavirus Main Proteinase (3CL ^{pro}) Structure: Basis for Design of anti-SARS Drugs", Science (1126/science.1085658), May 13, 2003, 1-10, USA			
✓		ATMAR <i>et al.</i> , "Diagnosis of Noncultivable Gastroenteritis Viruses, the Human Caliciviruses", Clin. Microbiol. Rev., Jan. 2001, 14(1):15-37, ASM, USA			

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	3645 1634
(Use as many sheets as necessary)				Examiner Name	To Be Assigned SALMON
Sheet	3	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
KS		"BARIC et al., "Subgenomic Negative-Strand RNA Function during Mouse Hepatitis Virus Infection", J. Virol., May 2000, 74(9):4039-4046, ASM, USA		
		BOOTH et al., "Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area", JAMA-Express, June 4, 2003, 289(21):1-9, AMA, Canada		
		BUDZILOWICZ et al., "Three Intergenic Regions of Coronavirus Mouse Hepatitis Virus Strain A59 Genome RNA Contain a Common Nucleotide Sequence That is Homologous to the 3' End of the Viral mRNA Leader Sequence", J. Virol., Mar. 1985, 53(3):834-840, ASM, USA		
		CHAN-YEUNG et al., "Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report", BMJ, Apr. 19, 2003, 326:850-852, USA		
		CHANG et al., "The UCUAAAC Promoter Motif Is Not required for High-Frequency Leader Recombination in Bovine Coronavirus Defective Interfering RNA", J. Virol., May 1996, 70(5):2720-2729, ASM, USA		
		CHANG et al., "A cis-Acting Function for the Coronavirus Leader in Defective Interfering RNA Replication", J. Virol., Dec. 1994, 68(12):8223-8231, ASM, USA		
		CURTIS et al., "Heterologous Gene Expression from Transmissible Gastroenteritis Virus Replicon Particles", J. Virol., Feb. 2002, 76(3):1422-1434, ASM, USA		
		de HAAN et al., "Coronaviruses Maintain Viability despite Dramatic Rearrangements of the Strictly Conserved Genome Organization", J. Virol., Dec. 2002, 76(24):12491-12502, ASM, USA		
		DONNELLY et al., "Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong, Lancet, May 7, 2003, pgs. 1-6, Elsevier Science Ltd., Great Britain		
		DRAZEN, "Case Clusters of the Severe Acute Respiratory Syndrome", N. Engl. J. Med., Mar. 23, 2003, pgs. 1-2, Mass. Med. Soc., USA		
		DROSTEN, "Preliminary RT-PCR Protocol for the Coronavirus suspected to be linked with SARS", Bernhard-Nocht-Institute for Tropical Medicine, Mar. 26, 2003, pgs. 1-2, Germany		
		DROSTEN et al., "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome", N. Engl. J. Med., Apr. 10, 2003, 348(20) 1967-1976, Mass. Med. Soc., USA		
		ENSERINK, "Scientists Chase Fast-Moving and Deadly Global Illness", Science, Mar. 21, 2003, 299:1822, USA		

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/825,757
		Filing Date	April 16, 2004
		First Named Inventor	LINNEN <i>et al.</i>
		Art Unit	1645 1634
(Use as many sheets as necessary)		Examiner Name	To Be Assigned SALMON
Sheet	4	of	9
		Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KS		EVANS et al., "Utilizing fowlpox virus recombinants to generate defective RNAs of the coronavirus infectious bronchitis virus", J. Gen. Virol., 2000, 81:2855-2865, Great Britain	
		FALSEY et al., "Novel coronavirus and severe acute respiratory syndrome", Lancet, Apr. 8, 2003, 2 pgs., Elsevier Science Ltd., Great Britain	
		FISCHER et al., "Analysis of a Recombinant Mouse Hepatitis Virus Expressing a Foreign Gene Reveals a Novel Aspect of Coronavirus Transcription", J. Virol., Jul. 1997, 71(7):5148-5160, ASM, USA	
		GERBERDING, "Faster...but Fast Enough? Responding to the Epidemic of Severe Acute Respiratory Syndrome", N. Engl. J. Med., 2003, 2 pgs., Mass. Med. Soc., USA	
		GOLD, "SARS genome patent: symptom or disease", Lancet, June 14, 2003, 361:1-2, Elsevier Science Ltd., Great Britain	
		GRADY et al., "Global Collaboration on SARS Bears Fruit", N.Y. Times, May 26, 2003, pgs. 1-5, N.Y. Times Co., USA	
		GRÖNDAHL et al., "Rapid Identification of Nine Microorganisms Causing Acute Respiratory Tract Infections by Single-Tube Multiplex Reverse Transcription-PCR: Feasibility Study", J. Clin. Microbiol., Jan. 1999, 37(1):1-7, ASM, USA	
		HÄIJEMA et al., "Switching Species Tropism: an Effective Way to Manipulate the Feline Coronavirus Genome", J. Virol., Apr. 2003, 77(8):4528-4538, ASM, USA	
		HISCOX et al., "Investigation of the Control of Coronavirus Subgenomic mRNA Transcription by Using T7-Generated Negative-Sense RNA Transcripts", J. Virol., Oct. 1995, 69(10):6219-6227, ASM, USA	
		HO, "Guideline on management of severe acute respiratory syndrome (SARS)", Lancet, Apr. 8, 2003, 3 pgs., Elsevier Ltd., USA	
		HOEY, "Updated SARS case definition using laboratory criteria", June 10, 2003, JAMC, 168(12):1566-1567, Can. Med. Assoc., Canada	
		HORIMOTO et al., "Pandemic Threat Posed by Avian Influenza A Viruses", Clin. Microbiol. Rev., Jan. 2001, 14(1):129-149, ASM, USA	
✓		HSIANG, "Coronaviridae Webpage", Feb. 1, 1999, pgs. 1-7, Stanford Univ., USA	

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645 1634
(Use as many sheets as necessary)				Examiner Name	To Be Assigned SALMON
Sheet	5	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
KS		HSUE et al., "A Bulged Stem-Loop Structure in the 3' Untranslated Region of the Genome of the Coronavirus Mouse Hepatitis Virus Is Essential for Replication", J. Virol., Oct. 1997, 71(10):7567-7578, ASM, USA		
		HSUE et al., "Characterization of an Essential RNA Secondary Structure in the 3' Untranslated Region of the Murine Coronavirus Genome", J. Virol., Aug. 2000, 74(15):6911-6921, ASM, USA		
		JEONG et al., "Evidence for Coronavirus Discontinuous Transcription", J. Virol., Apr. 1994, 68(4):2615-2623, ASM, USA		
		JOO et al., "Replication of Murine Coronavirus Defective Interfering RNA from Negative-Strand Transcripts", J. Virol., Sept. 1996, 70(9):5769-5776, ASM, USA		
		KEHL et al., "Evaluation of the Hexaplex Assay for Detection of Respiratory Viruses in Children", J. Clin. Microbiol., May 2001, 39(5):1696-1701, ASM, USA		
		KSIĄZEK et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", N. Engl. J. Med., Apr. 10, 2003, pgs. 1-12, Mass. Med. Soc., USA		
		LAI, "The making of infectious viral RNA: No size limit in sight", Proc. Natl. Acad. Sci., May 9, 2000, 97(10):5025-5027, USA		
		LAI et al, "Characterization of leader RNA sequences on the virion and mRNAs of mouse hepatitis virus, a cytoplasmic RNA virus", Proc. Natl. Acad. Sci., June 1984, 81:3626-3630, USA		
		LAI, "Coronavirus Leader-RNA-Primed Transcription: an Alternative Mechanism to RNA Splicing", BioEssays, undated, 5(6):257-260		
		LAI et al., "Presence of Leader Sequences in the mRNA of Mouse Hepatitis Virus", J. Virol., June 1983, 46(3):1027-1033, ASM, USA		
		LAI et al., "The Molecular Biology of Coronaviruses", Advances in Virus Research, 1997, 48:1-99, Academic Press Inc., USA		
		LAI et al., Further characterization of mRNA's of mouse hepatitis virus: presence of common 5'-end nucleotides", J. Virol., Feb. 1982, 41(2):557-565, ASM, USA (Abstract)		
		LAU et al., "A Real-time PCR for SARS-coronavirus incorporating target gene pre-amplification", Biochem. Biophys. Res. Comm., 2003, 312(4):1290-1296, Elsevier Inc., USA		
		LIAO et al., "Requirement of the 5'-End Genomic Sequence as an Upstream <i>cis</i> -Acting Element for Coronavirus Subgenomic mRNA transcription", J. Virol., Aug. 1994, 68(8):4727-4737, ASM, USA		

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645 1634
(Use as many sheets as necessary)				Examiner Name	To Be Assigned SALMON
Sheet	6	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
KS		LIN et al., "Identification of the <i>cis</i> -Acting Signal for Minus-Strand RNA Synthesis of a Murine Coronavirus: Implications for the Role of Minus-Strand RNA in RNA Replication and Transcription", J. Virol., Dec. 1994, 68(12):8131-8140, ASM, USA		
		LUMPKIN, Preliminary AdvaMed Recommendations: Ways to Speed Development of Diagnostic Tests for SARS and other Emerging Pathogens", SARS Diagnostics Meeting, 2003, 3 pgs., USA		
		MARRA et al., "The Genome Sequence of the SARS-Associated Coronavirus", Scienceexpress, May 1, 2003, pgs. 1-10, USA		
		MILLER et al., "Synthesis of Subgenomic RNAs by Positive-Strand RNA Viruses", Virology, 2000, 273:1-8, Academic Press Inc., USA		
		NAVAS et al., "Murine Coronavirus Spike Protein Determines the Ability of the Virus To Replicate in the Liver and Cause Hepatitis", J. Virol., Mar. 2001, 75(5):2452-2457, ASM, USA		
		NEWCOMB, "SARS and the New Economics of Biosecurity", Bio-Era, May 2003, pgs. 1-25, USA		
		NIE et al., "Advances in clinical diagnosis and treatment of severe acute respiratory syndrome", World J Gastroenterol, 2003, 9 (6):1139-1143, The WJG Press, China		
		ORTEGO et al., "Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome", J. Virol., Nov. 2002, 76(22):11518-11529, ASM, USA		
		PEIRIS et al., "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study", Lancet, May 24, 2003, 361:1767-1772, Elsevier Science Ltd., Great Britain		
		PEIRIS et al., "Coronavirus as a possible cause of severe acute respiratory syndrome", Lancet, Apr. 8, 2003, pgs. 1-7, Elsevier Science Ltd., Great Britain		
		POLLACK, "Scientists Race to Detect SARS, but First They Must Test the Test", N.Y. Times, June 3, 2003, pgs. 1-4, N.Y. Times Co., USA		
		POON et al., "Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)", Clin. Chem., Apr. 8, 2003, 49(7):1-3, The Assoc. for Clinical Chemistry, USA		
↓		POUTANEN et al., "Identification of Severe Acute Respiratory Syndrome in Canada", N. Engl. J. Med., Mar. 31, 2003, pgs. 1-11, Mass. Med. Soc., USA		

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1845 1634
(Use as many sheets as necessary)				Examiner Name	To Be Assigned SALMON
Sheet	7	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
KS		RUAN et al., "Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection" Lancet, May 9, 2003, 12 pgs., Elsevier Science Ltd., Great Britain		
		SAMPATHKUMAR et al., "SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures", Mayo Clin. Proc., 2003, 78:882-890, Mayo Foundation for Med. Edu. & Rsch., USA		
		SANCHEZ et al., "Targeted Recombination Demonstrates that the Spike Gene of Transmissible Gastroenteritis Coronavirus is a Determinant of Its Enteric Tropism and Virulence", J. Virol., Sept. 1999, 73(9):7607-7618, ASM, USA		
		SENANAYAKE et al., "Translation from the 5' Untranslated Region (UTR) of mRNA 1 Is Repressed, but That from the 5' UTR of mRNA 7 Is Stimulated in Coronavirus-Infected Cells", J. Virol., Oct. 1999, 73(10):8003-8009, ASM, USA		
		SEYBERT et al., "The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity", RNA, 2000, 6:1056-1068, Cambridge University Press, USA		
		SHEN et al., "Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis", Acta Pharmacol. Sin., June 2003, 24(6):505-511, China		
		SOLA et al., "Engineering the Transmissible Gastroenteritis Virus Genome as an Expression Vector Inducing Lactogenic Immunity", Apr. 2003, J. Virol., 77(7):4357-4369, ASM, USA		
		SPAAN et al., "Transcriptin Strategy of Coronaviruses: Fusion of Non-Contiguous Sequences During mRNA Synthesis", Molecular Biology and Pathogenesis of Coronaviruses, undated, pgs. 173-186, Plenum Press, USA		
		SPAAN et al., "Coronavirus mRNA synthesis involves fusion of non-contiguous sequences", EMBO J., 1983, 2(10):1839-1844, IRL Press Ltd., Great Britain		
		STIRRUPS et al., "Expression of reporter genes from the defective RNA CD-61 of the coronavirus infectious bronchitis virus", J. Gen. Virol., 2000, 81:1687-1698, Great Britain		
		STOHLMAN et al., "Specific Interaction between Coronavirus Leader RNA and Nucleocapsid Protein", Nov. 1988, J. Virol., 62(11):4288-4295, ASM, USA		
		TAGUCHI et al., "A Murine Coronavirus MHV-S Isolate from Persistently Infected Cells Has a Leader and Two Consensus Sequences Between the M and N Genes", Virology, 1994, 198:355-359, Academic Press, Inc., USA		

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/825,757
		Filing Date	April 16, 2004
		First Named Inventor	LINNEN <i>et al.</i>
		Art Unit	1645 1634
(Use as many sheets as necessary)		Examiner Name	To Be Assigned SALMON
Sheet	8	of	9
		Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KS		TAHARA et al., "Coronavirus Translational Regulation: Leader Affects mRNA Efficiency", Virology, 1994, 202:621-630, Academic Press Inc., USA	
		THIEL et al., "Viral Replicase Gene Products Suffice for Coronavirus Discontinuous Transcription", J. Virol., Jul. 2001, 75(14):6676-6681, ASM, USA	
		THIEL et al., "Infectious RNA transcribed <i>in vitro</i> from a cDNA copy of the human coronavirus genome cloned in a vaccinia virus", J. Gen. Virol., 2001, 82:1273-1281, Great Britain	
		TSANG et al., "A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong", N. Engl. J. Med., Mar. 31, 2003, pgs. 1-7, Mass. Med. Soc., USA	
		TYRRELL et al., "Coronaviruses: General Concepts", Graduate School of Biomedical Science: The University of Texas Medical Branch, Medmicro, 2003, Chpt. 60:1-6, USA	
		VABRET et al., "Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction", J. Virol. Meth., Sept. 2001, 97(1-2):59-66, Elsevier Science B.V., Amsterdam	
		VAN MARLE et al., "Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences", Proc. Natl. Acad. Sci., Oct. 12, 1999, 96(21):12056-12061, USA	
		WANG et al., "Microarray-based detection and genotyping of viral pathogens", Proc. Natl. Acad. Sci., Nov. 26, 2002, 99(24):15687-15692, USA	
		WANG et al., "The Leader RNA of Coronavirus Mouse Hepatitis Virus Contains an Enhancer-Like Element for Subgenomic mRNA Transcription", J. Virol., Nov. 2000, 74(22):10571-10580, ASM, USA	
		ZHANG et al., "Morphology and Morphogenesis of Severe Acute Respiratory Syndrome (SARS)-associated Virus", Acta Biochimica & Biophysica Sinica, 2003, 35(6):587-591, China	
		ZHANG et al., "Identification of a noncanonical signal for transcription of a novel subgenomic mRNA of mouse hepatitis virus: implication for the mechanism of coronavirus RNA transcription", Virology, 2000, 278(1):75-78, Academic Press Inc., USA	
		ZHANG et al., "Coronavirus Leader RNA Regulates and Initiates Subgenomic mRNA Transcription both in <i>trans</i> and in <i>cis</i> ", J. Virol., Aug. 1994, 68(8):4738-4746, ASM, USA	


Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Complete if Known**

Application Number	10/825,757
Filing Date	April 16, 2004
First Named Inventor	Jeffrey M. Linnen
Art Unit	1634
Examiner Name	TO BE ASSIGNED SALMON
Attorney Docket Number	GP146-04.UT


(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
KS		WO 2004/057021 A2	07-08-2004	Universite Laval	
		CN 1450172 A	10-22-2003	Hangzhou Huada Jene Res Ct	
		DE 203 15 159 U1	01-22-2004	Artus Ges Fuer Molekularbiolog	

12/29/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/825,757
		Filing Date	April 16, 2004
		First Named Inventor	Jeffrey M. Linnen
		Art Unit	1645 1634
		Examiner Name	To be assigned Salmon
Sheet 2	of 2	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KS		Drosten et al., "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome," N. Engl. J. Med., May 15, 2003, 348(20):1967-1976, Mass. Med. Society, Boston, MA, USA.	
		Grondahl et al., "Rapid Identification of Nine Microorganisms Causing Acute Respiratory Tract Infections by Single-Tube Multiplex Reverse Transcription-PCR: Feasibility Study," J. Clin. Microbiol., Jan. 1999, 37(1):1-7, ASM, Washington, D.C., USA.	
		Kehl et al., "Evaluation of the Hexaplex Assay for Detection of Respiratory Viruses in Children," J. Clin. Microbiol., May 2001, 39(5):1696-1701, ASM, Washington, D.C., USA.	
		Lau et al., "A real-time PCR for SARS-coronavirus incorporating target gene pre-amplification," Biochem. & Biophys. Research Comm. Dec. 26, 2003, 312(4):1290-1296, Academic Press Inc., Orlando, FL, USA.	
		Vabret et al., "Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction," J. Virol. Methods, 2001, 97(1-2):59-66, Elsevier Science B.V., Amsterdam, Netherlands.	
		Zhou et al., "One-step Duplex RT-PCT Assay for Detection SARS Associated Coronavirus," Virologica Sinica, June 2003, 18(3):232-236, Kexue Chubanshe, Beijing, China.	

Examiner Signature	/Katherine Salmon/	Date Considered	12/29/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.